EU/3/18/2034

About

On 27 June 2018, orphan designation (EU/3/18/2034) was granted by the European Commission to Apotex Europe B.V., the Netherlands, for deferiprone for the treatment of neurodegeneration with brain iron accumulation.

Key facts

Active substance
Deferiprone
Disease / condition
Treatment of neurodegeneration with brain iron accumulation
Date of decision
27/06/2018
Outcome
Positive
Orphan decision number
EU/3/18/2034

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Apotex Europe B.V.
Archimedesweg 2
2333 CN Leiden
The Netherlands
Tel. +31 (0) 71 5657 777
E-mail: jconnell@apopharma.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating